Trimbow

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
01-04-2022
Valmisteyhteenveto Valmisteyhteenveto (SPC)
01-04-2022

Aktiivinen ainesosa:

Beclometasone dipropionate, formoterol fumarate dihydrate, Glycopyrronium bromide

Saatavilla:

Chiesi Farmaceutici S.p.A.

ATC-koodi:

R03AL09

INN (Kansainvälinen yleisnimi):

beclometasone, formoterol, glycopyrronium bromide

Terapeuttinen ryhmä:

Drugs for obstructive airway diseases,

Terapeuttinen alue:

Pulmonary Disease, Chronic Obstructive

Käyttöaiheet:

Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. 

Tuoteyhteenveto:

Revision: 7

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2017-07-17

Pakkausseloste

                                95
B. PACKAGE LEAFLET
96
PACKAGE LEAFLET: INFORMATION FOR THE USER
TRIMBOW 87 MICROGRAMS/5 MICROGRAMS/9 MICROGRAMS PRESSURISED
INHALATION, SOLUTION
beclometasone dipropionate/formoterol fumarate
dihydrate/glycopyrronium
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trimbow is and what it is used for
2.
What you need to know before you use Trimbow
3.
How to use Trimbow
4.
Possible side effects
5.
How to store Trimbow
6.
Contents of the pack and other information
1.
WHAT TRIMBOW IS AND WHAT IT IS USED FOR
Trimbow is a medicine to help breathing that contains the three active
substances:
•
beclometasone dipropionate,
•
formoterol fumarate dihydrate and
•
glycopyrronium.
Beclometasone dipropionate belongs to a group of medicines called
corticosteroids which act to
reduce the swelling and irritation in your lungs.
Formoterol and glycopyrronium are medicines called long-acting
bronchodilators. They act in
different ways to relax the muscles in your airways, helping to open
the airways wider and allowing
you to breathe more easily.
Regular treatment with these three active substances helps to relieve
and prevent symptoms such as
shortness of breath, wheezing and cough in adult patients with
obstructive lung disease.
Trimbow is used for the regular treatment of
•
chronic obstructive pulmonary disease (COPD) in adults
•
asthma in adults.
Trimbow can reduce exacerbations (flare-ups) of COPD and asthma
symptoms.
COPD is a serious long-term disease in which the airways become
blocked and air sacs 
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised
inhalation, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose leaving the mouthpiece) contains 87
micrograms of beclometasone
dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9
micrograms of glycopyrronium (as
11 micrograms glycopyrronium bromide).
Each metered dose (the dose leaving the valve) contains 100 micrograms
of beclometasone
dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10
micrograms of glycopyrronium
(as 12.5 micrograms glycopyrronium bromide).
Excipient with known effect:
Trimbow contains 8.856 mg ethanol per actuation.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Pressurised inhalation, solution (pressurised inhalation)
Colourless to yellowish liquid solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Chronic obstructive pulmonary disease (COPD)
Maintenance treatment in adult patients with moderate to severe COPD
who are not adequately treated
by a combination of an inhaled corticosteroid and a long-acting
beta2-agonist or a combination of a
long-acting beta2-agonist and a long-acting muscarinic antagonist (for
effects on symptoms control
and prevention of exacerbations see section 5.1).
Asthma
Maintenance treatment of asthma, in adults not adequately controlled
with a maintenance combination
of a long-acting beta2-agonist and medium dose of inhaled
corticosteroid, and who experienced one or
more asthma exacerbations in the previous year.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is two inhalations twice daily.
The maximum dose is two inhalations twice daily.
Patients should be advised to take Trimbow every day even when
asymptomatic.
If symptoms arise in the period between doses, an inhaled,
short-acting beta2-agonist should be used
for immediate relief.
3
_Asthma _
When choosing the starting dose strength of Trimbow (87/5/9 micro
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto bulgaria 01-04-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 26-02-2021
Pakkausseloste Pakkausseloste espanja 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto espanja 01-04-2022
Pakkausseloste Pakkausseloste tšekki 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto tšekki 01-04-2022
Pakkausseloste Pakkausseloste tanska 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto tanska 01-04-2022
Pakkausseloste Pakkausseloste saksa 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto saksa 01-04-2022
Pakkausseloste Pakkausseloste viro 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto viro 01-04-2022
Pakkausseloste Pakkausseloste kreikka 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto kreikka 01-04-2022
Pakkausseloste Pakkausseloste ranska 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto ranska 01-04-2022
Pakkausseloste Pakkausseloste italia 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto italia 01-04-2022
Pakkausseloste Pakkausseloste latvia 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto latvia 01-04-2022
Pakkausseloste Pakkausseloste liettua 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto liettua 01-04-2022
Pakkausseloste Pakkausseloste unkari 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto unkari 01-04-2022
Pakkausseloste Pakkausseloste malta 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto malta 01-04-2022
Pakkausseloste Pakkausseloste hollanti 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto hollanti 01-04-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 26-02-2021
Pakkausseloste Pakkausseloste puola 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto puola 01-04-2022
Pakkausseloste Pakkausseloste portugali 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto portugali 01-04-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 26-02-2021
Pakkausseloste Pakkausseloste romania 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto romania 01-04-2022
Pakkausseloste Pakkausseloste slovakki 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto slovakki 01-04-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 26-02-2021
Pakkausseloste Pakkausseloste sloveeni 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto sloveeni 01-04-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 26-02-2021
Pakkausseloste Pakkausseloste suomi 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto suomi 01-04-2022
Pakkausseloste Pakkausseloste ruotsi 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto ruotsi 01-04-2022
Pakkausseloste Pakkausseloste norja 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto norja 01-04-2022
Pakkausseloste Pakkausseloste islanti 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto islanti 01-04-2022
Pakkausseloste Pakkausseloste kroatia 01-04-2022
Valmisteyhteenveto Valmisteyhteenveto kroatia 01-04-2022

Näytä asiakirjojen historia